Johnson & Johnson is a diversified healthcare company operating through two segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). It is a stock, not an exchange-traded fund. Because the widely followed analyst price targets are clustered only modestly above the current quote, this article uses a fallback objective rather than a forced consensus.
Individual current targets reviewed include UBS at $320, Scotiabank at $305, Citi at $303, TD Cowen at $300, Morgan Stanley at $292, Wells Fargo and Guggenheim at $287, J.P. Morgan at $285, RBC Capital and Goldman Sachs at $280, BofA Securities at $275, Leerink Partners at $272, Bernstein at $270, and Stifel at $260. The arithmetic mean of the full set is roughly $288 — only about 4% above the latest price. Even averaging only the targets above the current price yields about $294, still under 6% higher. Because neither clears a meaningful 10% threshold, this article evaluates a $310 technical milestone, a level commonly cited in market commentary as the shares approach record territory above the $282 prior high and the $300 psychological mark.
At $276.22, reaching $310 implies upside of roughly 12.2%, which constitutes a substantial move for a mega-cap that has already climbed sharply. The stock has roughly doubled off its November 2025 low of about $185 and carries a market capitalization near $665 billion. After setting a 52-week high of $282.02 in late October, the shares pulled back amid an initially disappointing quarterly report in early November before recovering on positive pipeline news, including new clinical data for the Impella heart pump franchise and an FDA approval for RYBREVANT in head and neck cancer. Reaching $310 would require not only reclaiming the prior high but also sustaining momentum beyond a widely watched round-number level — a scenario that depends on continued earnings delivery rather than multiple expansion alone.
Johnson & Johnson reported roughly 6% sales growth and 8.1% adjusted diluted EPS (earnings per share) growth in 2025, and management guided to about 6.7% sales growth and 6.9% adjusted EPS growth at the midpoint for 2026. The oncology franchise has been a standout, with growth led by Darzalex and Carvykti, while electrophysiology posted double-digit gains. A strong new-product cycle is helping offset the loss of exclusivity on the immunology blockbuster Stelara, which represented a large headwind to 2025 sales. Recent regulatory wins and positive device data add to the pipeline narrative, and the shares offer a dividend yield near 1.9%, which can support demand from income-focused investors during periods of market volatility.
Stelara erosion and the broader patent-expiration wall across the pharmaceutical sector remain a structural drag, and the company must repeatedly prove that new products can fill the gap. Long-running talc and other product-liability litigation continues to be a financial and reputational overhang. The trailing P/E (price-to-earnings ratio) near 40x reflects one-time items, yet analysts still debate whether the stock's premium valuation leaves room for further multiple expansion; some have explicitly argued that additional re-rating appears unlikely. A quarterly report that disappoints — as the early November print initially did — can quickly reverse momentum, and the shares remain sensitive to sector rotation away from defensive healthcare names.
The most important resistance sits at the 52-week high of $282.02, followed by the psychological $300 level. A sustained break above $282 would mark new record territory and could open a path toward the $300–$310 zone. On the downside, the $265–$266 area — home to recent October-to-November lows and the 50-day moving average near $266 — represents initial support, with the 200-day moving average near $248 acting as a longer-term floor.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms may apply different frameworks. Investors should watch the next quarterly earnings release and updated guidance, revisions to individual analyst price targets, oncology and immunology data readouts, progress on new product launches, and any developments in the talc litigation. Changes in broader interest-rate expectations and sector rotation into or out of healthcare can also influence the multiple the market is willing to pay.
AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a name like Johnson & Johnson that is trading near multi-year highs, these signals can help traders spot shifting momentum and identify opportunities or risks earlier than manual review alone. Traders can use the tool to discover new setups, monitor existing positions, and track changing trends more efficiently.
The $310 objective is a technical milestone rather than an analyst consensus, and it sits about 12% above the latest close. The strongest case rests on a genuine new-product cycle, solid 2026 growth guidance, and recent regulatory and clinical momentum. The principal obstacles are Stelara patent erosion, litigation, an elevated valuation, and the fact that the average analyst price target of roughly $288 implies far more limited upside — a reminder of meaningful disagreement even among bullish firms. Reaching $310 would require the stock to decisively clear its prior record high and the $300 level. Investors should focus on earnings delivery, pipeline catalysts, and analyst revisions rather than any single price point.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with GSK. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then GSK could also see price increases.
| Ticker / NAME | Correlation To JNJ | 1D Price Change % | ||
|---|---|---|---|---|
| JNJ | 100% | +1.43% | ||
| GSK - JNJ | 53% Loosely correlated | -0.16% | ||
| ABBV - JNJ | 53% Loosely correlated | +1.07% | ||
| NVS - JNJ | 52% Loosely correlated | +0.38% | ||
| MRK - JNJ | 48% Loosely correlated | -0.14% | ||
| AMGN - JNJ | 47% Loosely correlated | +0.03% | ||
More | ||||